logo
logo

Cxl Ophthalmics Announces $32 Million Series A Investment Round Led By Axa Im Alts, Through Its Global Health Private Equity Strategy

Sep 30, 2022•almost 3 years ago

Amount Raised

$32 Million

Round Type

series a

SherbornTherapeuticsMedical

Description

CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced it has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists. The new investments will support the advancement of CXL Ophthalmics’ (CXLO) transformative cross-linking system, EpiSmart®, through Phase 3 trials on the way to a New Drug Application with FDA.

Company Information

Company

CXL Ophthalmics

Location

Sherborn, Massachusetts, United States

About

CXL Ophthalmics (CXLO) is developing innovative treatments for corneal diseases with the goal of saving and improving vision for millions of patients around the world. EpiSmart, its transformative cross-linking system targeting keratoconus, a common type of corneal ectasia, is designed to be minimally invasive with reduced discomfort and a significantly reduced recovery time versus current standards of care. CXLO’s elegant approach will elevate the standard of care by enabling the treatment of both eyes simultaneously and eliminating the need for further deterioration. With a true Epi-On approach that does not disrupt the epithelium, CXLO is striving to deliver safer and more accessible vision-preserving care to millions of patients globally.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People